Entrada Therapeutics, Inc.

TRDA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$65,626-$6,685-$94,616-$51,158
Dep. & Amort.$3,773$2,841$1,895$1,117
Deferred Tax$0$0$0$0
Stock-Based Comp.$17,915$13,111$0$2,526
Change in WC-$118,853$136,315-$11,111-$3,421
Other Non-Cash-$10,018-$5,779$10,046$74
Operating Cash Flow-$41,557$139,803-$93,786-$50,862
Investing Activities
PP&E Inv.-$3,158-$5,614-$2,887-$4,580
Net Acquisitions$0$0$0$0
Inv. Purchases-$437,717-$407,207-$221,977$0
Inv. Sales/Matur.$413,077$274,426$76,214$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$27,798-$138,395-$148,650-$4,580
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$99,608$19,407$479$190,691
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$3,356$1,630$0$116,770
Financing Cash Flow$102,964$21,037$479$307,461
Forex Effect$0$0-$3,950$0
Net Chg. in Cash$33,609$22,445-$245,907$252,019
Supplemental Information
Beg. Cash$71,552$49,107$291,064$39,045
End Cash$105,161$71,552$45,157$291,064
Free Cash Flow-$44,715$134,189-$96,673-$55,442